Бен Голдакр - Вся правда о лекарствах. Мировой заговор фармкомпаний

31. Tiefer L. Female Sexual Dysfunction: A Case Study of Disease Mongering and Activist Resistance. PLoS Med. 2006 Apr 11;3(4):e178.

32. Ibid.

33. Ibid.

34. Testosterone Patches for Female Sexual Dysfunction. DTB. 2009 Mar 1;47(3):30-4.

35. Durand M. Pharma’s Advocacy Dance [Internet]. Successful Product Manager’s Handbook. 2006 [cited 2012 Mar 26]. Available from: http://www.pharmexec.com/pharmexec/ Articles/Pharmas-Advocacy-Dance/ArticleStandard/Article/ detail/377999.

36. 11 August 2010 HAI Europe Research Article Patient & Consumer Organisations at the EMA: Financial Disclosure & Transparency. Written by Katrina Perehudoff and Teresa Leonardo Alves. 11 August 2010 HAI Europe Factsheet Patient & Consumer Organisations at the EMA: Financial Disclosure & Transparency.

37. HAI. The Patient & Consumer Voice and Pharmaceutical Industry Sponsorship [Internet]. [cited 2012 Mar 26]. Available from: http://apps.who.int/medicinedocs/en/m/abstract/Js17767en/

38. ‘Drug firms bankroll attacks on NHS’ Independent, 1 October 2008.

39. ‘Analysis: Are patient protests being manipulated?’ Independent, 1 October 2008.

40. Health chief attacks drug giants over huge profits UK news The Observer [Internet]. [cited 2012 Mar 26]. Available from: http://www.guardian.co.uk/uk/2008/aug/17/pharmaceuticals. nhs.

41. Spurling GK, Mansfield PR, Montgomery BD, Lexchin J, Doust J, Othman N, et al. Information from Pharmaceutical Companies and the Quality, Quantity, and Cost of Physicians’ Prescribing: A Systematic Review. PLoS Med. 2010 Oct 19;7(10):e1000352.

42. Azoulay P. Do pharmaceutical sales respond to scientific evidence? Journal of Economics & Management Strategy. 2002;11(4): 551-94.

43. Heimans L, van Hylckama Vlieg A, Dekker FW. Are claims of advertisements in medical journals supported by RCTs? Neth J Med. 2010 Jan;68(1):46-9.

44. Villanueva P, Peiro S, Librero J, Pereiro I. Accuracy of pharmaceutical advertisements in medical journals. The Lancet. 2003 Jan;361(9351):27–32.

45. Spielmans GI, Thielges SA, Dent AL, Greenberg RP. The accuracy of psychiatric medication advertisements in medical journals. J. Nerv. Ment. Dis. 2008 Apr;196(4):267-73.

46. Van Winkelen P, van Denderen JS, Vossen CY, Huizinga TWJ, Dekker FW, for the SEDUCE study group. How evidence-based are advertisements in journals regarding the subspecialty of rheumatology? Rheumatology. 2006 Sep 1;45(9):1154-7.

47. Othman N, Vitry A, Roughead EE. Quality of Pharmaceutical Advertisements in Medical Journals: A Systematic Review. PLoS ONE. 2009 Jul 22;4(7):e6350.

48. Gibson L. UK government fails to tackle weaknesses in drug industry. BMJ. 2005 Sep 10;331(7516):534-40.

49. Wilkes MS, Kravitz RL. Policies, practices, and attitudes of North American medical journal editors. J Gen Intern Med. 1995 Aug;10(8):443-50.

50. Via: Cooper RJ, Schriger DL, Wallace RC, Mikulich VJ, Wilkes MS. The Quantity and Quality of Scientific Graphs in Pharmaceutical Advertisements. J Gen Intern Med. 2003 Apr;18(4):294-7. ‘Polling of the audience occurred as part of the discussion of the oral presentation of this abstract’. FOURTH INTERNATIONAL CONGRESS ON PEER REVIEW [Internet]. Available from: http://www.amaassn.org/public/peer/prc_program2001.htm#ABSTRACTS.

51. You might also enjoy some of the books written by retired drug reps, such as: Reidy J. Hard Sell: The Evolution of a Viagra Salesman. 1st ed. Andrews McMeel Publishing; 2005.

52. Rockoff JD. Drug Reps Soften Their Sales Pitches. Wall Street Journal [Internet]. 2012 Jan 10 [cited 2012 Mar 22]; Available from: http://online.wsj.com/article/ SB100014240529702043313 04577142763014776148.html

53. Fugh-Berman A, Ahari S. Following the Script: How Drug Reps Make Friends and Influence Doctors. PLoS Med. 2007 Apr;4(4).

54. Soyk, C., B. Pfefferkorn, P. McBride, and R. Rieselbach. 2010. Medical student exposure to and attitudes about pharmaceutical companies. World Medical Journal 109: 142–148.

55. Fischer MA, Keough ME, Baril JL, Saccoccio L, Mazor KM, Ladd E, et al. Prescribers and Pharmaceutical Representatives: Why Are We Still Meeting? J Gen Intern Med. 2009 Jul;24(7):795–801.

56. Morgan MA, Dana J, Loewenstein G, Zinberg S, Schulkin J. Interactions of doctors with the pharmaceutical industry. J Med Ethics. 2006 Oct;32(10):559-63.

57. B Hodges, ‘Interactions with the pharmaceutical industry: experiences and attitudes of psychiatry residents, interns and clerks,’ CMAJ: Canadian Medical Association Journal = Journal De l’Association Medicale Canadienne 153, no. 5 (September 1, 1995): 553–559.

58. Spurling GK, Mansfield PR, Montgomery BD, Lexchin J, Doust J, Othman N, et al. Information from Pharmaceutical Companies and the Quality, Quantity, and Cost of Physicians’ Prescribing: A Systematic Review. PLoS Med. 2010 Oct 19;7(10):e1000352.

59. MM Chren and CS Landefeld, ‘Physicians’ behavior and their interactions with drug companies. A controlled study of physicians who requested additions to a hospital drug formulary,’ JAMA: The Journal of the American Medical Association 271, no. 9 (March 2, 1994): 684–689.

60. Ladd EC, Mahoney DF, Emani S. ‘Under the radar’: nurse practitioner prescribers and pharmaceutical industry promotions. Am J Manag Care. 2010;16(12):e358-362.

61. Zipkin DA, Steinman MA. Interactions Between Pharmaceutical Representatives and Doctors in Training. J Gen Intern Med. 2005 Aug;20(8):777-86.

62. Spingarn RW, Berlin JA, Strom BL. When pharmaceutical manufacturers’ employees present grand rounds, what do residents remember? Acad Med. 1996 Jan;71(1):86-8.

63. Wazana A. Physicians and the Pharmaceutical Industry: Is a Gift Ever Just a Gift? JAMA. 2000 Jan 19;283(3):373-80.

64. Lurie N, Rich EC, Simpson DE, Meyer J, Schiedermayer DL, Goodman JL, et al. Pharmaceutical representatives in academic medical centers: interaction with faculty and housestaff. J Gen Intern Med. 1990 Jun;5(3):240-3.

65. Fugh-Berman A, Ahari S. Following the Script: How Drug Reps Make Friends and Influence Doctors. PLoS Med. 2007 Apr;4(4).

66. Ibid.

67. Sismondo S. How pharmaceutical industry funding affects trial outcomes: Causal structures and responses. Social Science & Medicine. 2008;66(9):1909-14.

68. Completed Cases PMCPA Website [Internet]. [cited 2012 Mar 26]. Available from: http://www.pmcpa.org.uk/?q=node/868

69. Completed Cases PMCPA Website [Internet]. [cited 2012 Mar 26]. Available from: http://www.pmcpa.org.uk/?q=node/883

70. Orlowski JP, Wateska L. The effects of pharmaceutical firm enticements on physician prescribing patterns. There’s no such thing as a free lunch. Chest. 1992 Jul;102(1):270-3.

71. Steinbrook R. For sale: physicians’ prescribing data. N. Engl. J. Med. 2006 Jun 29;354(26):2745-7.

72. Physician Data Restriction Program (PDRP) [Internet]. [cited 2012 Mar 22]. Available from: http://www.ama-assn.org/ama/ pub/about-ama/physician-data-resources/ama-databaselicensing/amas-physician-data-restriction-program.page

73. Outterson K. Higher First Amendment Hurdles for Public Health Regulation. New England Journal of Medicine. 2011 Aug 18;365(7):e13.

74. Zipkin DA, Steinman MA. Interactions Between Pharmaceutical Representatives and Doctors in Training. J Gen Intern Med. 2005 Aug;20(8):777-86.

75. Wislar JS, Flanagin A, Fontanarosa PB, DeAngelis CD. Honorary and ghost authorship in high impact biomedical journals: a cross sectional survey. BMJ. 2011 Oct 25;343(oct25 1):d6128-d6128.

76. G0tzsche PC, Hrobjartsson A, Johansen HK, Haahr MT, Altman DG, Chan A-W. Ghost Authorship in Industry-Initiated Randomised Trials. PLoS Med. 2007 Jan 16;4(1):e19.

77. ‘Ghost writing in the medical literature’ 111th Congress, United States Senate Committee on Finance Sen. Charles E. Grassley, 2010. [cited 2012 Mar 24]. Available from: http://www.grassley. senate.gov/about/upload/Senator-GrassleyReport.pdf

78. Richard Horton PI 108, House of Commons Health Minutes of Evidence [Internet]. [cited 2012 Mar 24]. Available from: http://www.publications.parliament.uk/pa/cm200405/ cmselect/ cmhealth/42/4121604.htm

79. Galanter M, Galanter M, Felstiner WLF, Friedman LM, Girth M, Goldstein P, et al. Why the haves come out ahead: Speculations on the limits of legal change. Law Society Review. 1974;9:95-169.

80. Lilly ‘Ghostwrote’ Articles to Market Drug, Files Say (Update2) Bloomberg [Internet]. [cited 2012 Mar 24]. Available from: http:// www.bloomberg.com/apps/news?pid=newsarchive&sid=a6yFu_ t9NyTY

81. http://www.psychiatrynorthwest.co.uk/general_adult_ psychiatry/spr_posts/salford-haddad/index.html

82. Medical Press Pre-Launch Feature Outline, Zyprexa MDL 1596, confidential subject to protection order ZY200187608. http://zyprexalitigationdocuments.com/per cent5Cdocuments per cent5CConfidentiality-Challenge per cent5CDocschallenged-in-10-3list per cent5C145-ZY200187608-7614.pdf

83. Drug Industry Document Archive [Internet]. [cited 2012 Mar 24]. Available from: http://dida.library.ucsf.edu/

84. Drug Industry Document Archive Search Results [Internet]. [cited 2012 Mar 24]. Available from: http://dida.library.ucsf. edu/ tid/anu38h10

85. Ibid.

86. Ross, J.S., K.P. Hill, D.S. Egilman, and H.M. Krumholz. 2008. Guest authorship and ghostwriting in publications related to rofecoxib: A case study of industry documents from rofecoxib litigation. Journal of the American Medical Association 299: 18001812.

87. POGO Letter to NIH on Ghostwriting Academics [Internet]. Project On Government Oversight. [cited 2012 Mar 24]. Available from: http://www.pogo.org/pogo-files/letters/publichealth/ ph-iis-20101129.html

88. http://www.nytimes.com/2010/11/30/business/30drug.html

89. http://pogoblog.typepad.com/pogo/gw-attachment-e.html

90. Lacasse JR, Leo J. Ghostwriting at Elite Academic Medical Centers in the United States. PLoS Med. 2010 Feb 2;7(2):e1000230.

91. Matheson A. How Industry Uses the ICMJE Guidelines to Manipulate Authorship And How They Should Be Revised. PLoS Med. 2011;8(8):e1001072.

92. Dyer O. Journal rejects article after objections from marketing department. BMJ. 2004 Jan 31;328(7434):244-b-244.

93. Fugh-Berman A, Alladin K, Chow J. Advertising in Medical Journals: Should Current Practices Change? PLoS Med. 2006 May 2;3(6):e130.

94. Becker A, Dorter F, Eckhardt K, Viniol A, Baum E, Kochen MM, et al. The association between a journal’s source of revenue and the drug recommendations made in the articles it publishes. CMAJ. 2011 Feb 28 Available from: http://www.cmaj.ca/content/early/2011/02/28/cmaj.100951

95. Smith R. Medical Journals Are an Extension of the Marketing Arm of Pharmaceutical Companies. PLoS Med. 2005 May 17;2(5):e138.

96. AUTH/2424/8/11 and AUTH/2425/8/11 General Practitioner v Boehringer Ingelheim and Lilly. Available from: http://www. pmcpa.org.uk/?q=node/998.

97. Handel AE, Patel SV, Pakpoor J, Ebers GC, Goldacre B, Ramagopalan SV. High reprint orders in medical journals and pharmaceutical industry funding: case-control study. BMJ. 2012 Jun 28;344(jun28 1):e4212-e4212.

98. Jefferson T, Di Pietrantonj C, Debalini MG, Rivetti A, Demicheli V. Relation of study quality, concordance, take home message, funding, and impact in studies of influenza vaccines: systematic review. BMJ. 2009 Feb 12;338(feb12_2):b354.

99. http://classic.the-scientist.com/blog/display/55679/

100. http://elsevier.com/wps/find/authored _newsitem.cws_home/ companynews05_01203

101. Bowman MA. The impact of drug company funding on the content of continuing medical education. Mobius: A Journal for Continuing Education Professionals in Health Sciences. 1986 Jan 1;6(1):66-9.